WO2012008807A3 - ＴＧａｓｅ２ 및 ＶＨＬ의 신장암 진단 마커로서의 용도 - Google Patents

ＴＧａｓｅ２ 및 ＶＨＬ의 신장암 진단 마커로서의 용도 Download PDF

Info

Publication number
WO2012008807A3
WO2012008807A3 PCT/KR2011/005249 KR2011005249W WO2012008807A3 WO 2012008807 A3 WO2012008807 A3 WO 2012008807A3 KR 2011005249 W KR2011005249 W KR 2011005249W WO 2012008807 A3 WO2012008807 A3 WO 2012008807A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell carcinoma
renal cell
composition
vhl
kit
Prior art date
Application number
PCT/KR2011/005249
Other languages
English (en)
French (fr)
Other versions
WO2012008807A2 (ko
Inventor
김수열
홍경만
Original Assignee
국립암센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 국립암센터 filed Critical 국립암센터
Publication of WO2012008807A2 publication Critical patent/WO2012008807A2/ko
Publication of WO2012008807A3 publication Critical patent/WO2012008807A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

본 발명은 TGase2(Transglutaminase 2) 및 VHL(Von Hippel-Lindau) 중 하나 이상의 발현 수준을 측정하는 제제를 포함하는 신장암 진단용 조성물, 상기 조성물을 포함하는 신장암 진단용 키트 및 상기 조성물 또는 키트를 이용하여 신장암을 진단하는 방법에 관한 것이다. 본 발명의 신장암 진단용 조성물 및 키트를 이용하면, 신장암을 조기에 진단할 수 있으므로, 보다 안전하고 효과적인 신장암의 예방 및 치료에 널리 활용될 수 있을 것이다.
PCT/KR2011/005249 2010-07-15 2011-07-15 ＴＧａｓｅ２ 및 ＶＨＬ의 신장암 진단 마커로서의 용도 WO2012008807A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0068558 2010-07-15
KR1020100068558A KR101267580B1 (ko) 2010-07-15 2010-07-15 신장암 진단 마커로서의 트란스글루타미나제2 및 이를 이용한 신장암 진단 용도

Publications (2)

Publication Number Publication Date
WO2012008807A2 WO2012008807A2 (ko) 2012-01-19
WO2012008807A3 true WO2012008807A3 (ko) 2012-05-18

Family

ID=45469964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/005249 WO2012008807A2 (ko) 2010-07-15 2011-07-15 ＴＧａｓｅ２ 및 ＶＨＬ의 신장암 진단 마커로서의 용도

Country Status (2)

Country Link
KR (1) KR101267580B1 (ko)
WO (1) WO2012008807A2 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101456696B1 (ko) * 2012-11-02 2014-11-04 국립암센터 ＴＧａｓｅ2 및 ｐ53을 이용한 신장암 항암제 스크리닝 방법
KR102061814B1 (ko) 2016-09-28 2020-01-03 가톨릭대학교 산학협력단 신장암 환자의 예후 진단 및 치료 전략 결정용 성별 특이적 마커
WO2018062862A1 (ko) 2016-09-28 2018-04-05 가톨릭대학교 산학협력단 신장암 환자의 예후 진단 및 치료 전략 결정용 성별 특이적 마커
KR20190017465A (ko) 2017-08-11 2019-02-20 가톨릭대학교 산학협력단 신장암 환자의 예후 진단용 마커
KR20190030833A (ko) 2017-09-15 2019-03-25 가톨릭대학교 산학협력단 신장암 환자의 예후 진단 및 치료 전략 결정용 연령 특이적 마커
KR20190067570A (ko) 2017-12-07 2019-06-17 가톨릭대학교 산학협력단 신장암 환자의 예후 진단 및 치료 전략 결정용 병리등급 특이적 마커
KR102084658B1 (ko) 2018-06-27 2020-03-05 가톨릭대학교 산학협력단 신장암 환자의 예후 진단 및 치료 전략 결정용 전이 특이적 마커
KR20200104106A (ko) 2019-02-26 2020-09-03 가톨릭대학교 산학협력단 신장암 환자의 치료 전략 결정 및 예후 진단용 재발 특이적 마커
KR20210096801A (ko) 2020-01-29 2021-08-06 가톨릭대학교 산학협력단 종양형태에 따른 신장암의 예후 진단용 조성물 및 키트
KR20210096799A (ko) 2020-01-29 2021-08-06 가톨릭대학교 산학협력단 연령에 따른 신장암의 예후 진단용 조성물 및 키트
KR20210096800A (ko) 2020-01-29 2021-08-06 가톨릭대학교 산학협력단 성별에 따른 신장암의 예후 진단용 조성물 및 키트
KR20210096798A (ko) 2020-01-29 2021-08-06 가톨릭대학교 산학협력단 신장암의 예후 진단용 조성물 및 이를 포함하는 키트
KR20210105134A (ko) 2020-02-18 2021-08-26 가톨릭대학교 산학협력단 유두형 신장암의 재발 및 예후 예측용 바이오 마커 및 이의 용도
KR20210107561A (ko) 2020-02-24 2021-09-01 가톨릭대학교 산학협력단 유두형 신장암의 병리학적 병기 진단용 바이오 마커 및 이의 용도
KR20220129448A (ko) 2021-03-16 2022-09-23 (주)엠디바이오랩 트랜스글루타미나제-2 활성 억제용 1h-벤조이미아졸-4,7-디온 유도체 및 이를 함유하는 항암제 조성물
KR20210040921A (ko) 2021-04-06 2021-04-14 가톨릭대학교 산학협력단 신장암 환자의 치료 전략 결정 및 예후 진단용 재발 특이적 마커

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JANG, J. H. ET AL.: "Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis", CANCER LETT., vol. 287, no. 2., 28 January 2010 (2010-01-28), pages 224 - 230, XP026824296 *
LINEHAN, W. M. ET AL.: "Molecular diagnosis and therapy of kidney cancer", ANNU. REV. MED., vol. 61, February 2010 (2010-02-01), pages 329 - 343, XP055021613, DOI: doi:10.1146/annurev.med.042808.171650 *
NICKERSON, M. L. ET AL.: "Improved identification ofvon Hippel-Lindau gene alterations in clear cell renal tumors", CLIN. CANCER RES., vol. 14, no. 15, 1 August 2008 (2008-08-01), pages 4726 - 4734 *
WYKOFF, C. C. ET AL.: "Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling", ONCOGENE, vol. 19, no. 54, 14 December 2000 (2000-12-14), pages 6297 - 6305 *

Also Published As

Publication number Publication date
KR20120007826A (ko) 2012-01-25
WO2012008807A2 (ko) 2012-01-19
KR101267580B1 (ko) 2013-05-28

Similar Documents

Publication Publication Date Title
WO2012008807A3 (ko) ＴＧａｓｅ２ 및 ＶＨＬ의 신장암 진단 마커로서의 용도
MX341191B (es) Metodos y composiciones para diagnostico y prognosis de lesion renal y falla renal.
WO2007028161A3 (en) Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
BR112012009262A2 (pt) ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
WO2013134786A3 (en) Biomarker compositions and methods
NZ712823A (en) Molecular diagnostic test for cancer
MX2018004067A (es) Extinguidor que contiene nanomaterial conjugado con polimero soluble en agua y su uso.
WO2013022995A3 (en) Biomarker compositions and methods
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
WO2012174282A3 (en) Biomarker compositions and methods
WO2011160063A3 (en) Methods and materials for assessing loss of heterozygosity
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2013033074A3 (en) Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
CA2726071A1 (en) Blood glucose monitoring device
BR112014013544A8 (pt) materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata
MX2011008323A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
WO2012017430A3 (en) Microrna patterns for the diagnosis, prognosis and treatment of melanoma
WO2014100717A3 (en) Compositions, methods and kits for diagnosis of lung cancer
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
WO2008067806A3 (de) Diagnose und risikostratifizierung von herzinsuffizienz mittels neurophysin
WO2009022988A3 (en) Vhz for diagnosis and treatment of cancer
WO2008005771A3 (en) Methods for identifying patients with increased risk of an adverse cardiovascular event
WO2014177867A3 (en) Differentially expressed biomarkers for alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11807092

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11807092

Country of ref document: EP

Kind code of ref document: A2